Reasons for Amit Sachdev’s Shares Unload of Vertex Pharmaceuticals (VRTX)’s Stock; Cypress Capital Group Boosted By $760,475 Its Jpmorgan Chase & Co (JPM) Position

The EVP – CRO of Vertex Pharmaceuticals Inc Ma, Amit Sachdev is in the stock market news today. It was published in a form filled by Amit Sachdev and submitted to the U.S. SEC on 14/02/2018, he sold 17,796 shares from the company worth $2,684,411 U.S. Dollars. The shares average price was $150.8. In the last month, he also unloaded 71,601 shares that are worth approx $11,587,610 USD. Currently, Amit Sachdev has a total of 59,759 shares or 0.02% of the Company’s market cap.

Cypress Capital Group increased Jpmorgan Chase & Co (JPM) stake by 10.5% reported in 2017Q3 SEC filing. Cypress Capital Group acquired 8,005 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.04%. The Cypress Capital Group holds 84,220 shares with $8.04 million value, up from 76,215 last quarter. Jpmorgan Chase & Co now has $393.96 billion valuation. The stock increased 2.31% or $2.6 during the last trading session, reaching $115.03. About 15.19 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since February 15, 2017 and is uptrending. It has outperformed by 17.04% the S&P500.

Since August 31, 2017, it had 0 insider purchases, and 37 sales for $109.10 million activity. Parini Michael sold $600,680 worth of stock. $116,511 worth of stock was sold by Graney Thomas on Tuesday, January 2. 10,753 shares were sold by Bhatia Sangeeta N., worth $1.68 million. SMITH IAN F had sold 75,000 shares worth $10.88 million. Chodakewitz Jeffrey sold $616,465 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, February 1. 4,520 shares valued at $736,800 were sold by Sachdev Amit on Monday, February 5. 8,969 shares were sold by Arbuckle Stuart A, worth $1.52M on Wednesday, January 24.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It improved, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Wells Fargo Co Mn stated it has 1.98 million shares. 13,956 are owned by Convergence Prtnrs Ltd Liability. Jane Street Grp Inc Limited Liability owns 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 12,255 shares. 43,305 were accumulated by Cornerstone Cap Mgmt Limited Liability. Sio Mgmt Limited Liability Corporation reported 14,874 shares. Moreover, Canada Pension Plan Invest Board has 0.06% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Edgewood Management Limited Com has 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bessemer Grp Inc holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 702 shares. Ngam L P holds 0.13% or 82,137 shares. Texas Permanent School Fund, Texas-based fund reported 69,870 shares. 81 were accumulated by Tradewinds Cap Ltd. Los Angeles Capital & Equity Inc has 85,339 shares for 0.07% of their portfolio. 12,643 are owned by First Republic Inv Mngmt Inc. Hightower Ltd Llc holds 0.02% or 15,987 shares in its portfolio. Citigroup accumulated 138,351 shares.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $178.31’s average target is 13.39% above currents $157.26 stock price. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was upgraded by H.C. Wainwright to “Buy” on Friday, October 30. The firm earned “Outperform” rating on Tuesday, March 8 by Leerink Swann. The firm earned “Hold” rating on Wednesday, July 19 by H.C. Wainwright. On Thursday, September 29 the stock rating was maintained by Jefferies with “Buy”. The stock has “Buy” rating by Maxim Group on Wednesday, July 19. The rating was downgraded by UBS on Wednesday, July 19 to “Hold”. The rating was upgraded by Cowen & Co on Wednesday, July 19 to “Outperform”. BMO Capital Markets maintained it with “Buy” rating and $189.0 target in Friday, October 20 report. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, January 31 report. The stock has “Buy” rating by Stifel Nicolaus on Friday, September 29.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.83 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 151.21 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

The stock increased 2.02% or $3.12 during the last trading session, reaching $157.26. About 1.99M shares traded or 13.96% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 15, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Since August 21, 2017, it had 1 insider buy, and 10 sales for $23.24 million activity. Scher Peter also sold $1.91M worth of JPMorgan Chase & Co. (NYSE:JPM) shares. 9,194 shares valued at $1.03M were sold by Lake Marianne on Saturday, January 13. 16,434 JPMorgan Chase & Co. (NYSE:JPM) shares with value of $1.84M were sold by BACON ASHLEY. 65,101 shares were sold by Erdoes Mary E., worth $7.31M. Shares for $825,327 were bought by CROWN JAMES S on Tuesday, January 16. On Saturday, January 13 the insider Friedman Stacey sold $1.99M. The insider Petno Douglas B sold 48,344 shares worth $5.43 million.

Cypress Capital Group decreased Aetna Inc (NYSE:AET) stake by 2,934 shares to 1,548 valued at $246,000 in 2017Q3. It also reduced Paychex Inc (NASDAQ:PAYX) stake by 6,507 shares and now owns 134,527 shares. Cvs Health Corp (NYSE:CVS) was reduced too.